The UK’s pioneering licensed IVF technique to reduce the risk of mitochondrial diseases carried out in Newcastle, UK, has seen eight babies born, published research shows. All eight babies ...

By MARIA CHENG and LAURA UNGAR The Associated Press LONDON Eight healthy babies were born in Britain with the help of an experimental technique that uses DNA from three people to help mothers ...

Plains All American's story isn't exactly a bad one. Crude oil is highly likely to remain important for decades to come, and bolt-on acquisitions can probably help keep the business growing for years.

Plains All American just announced a plan to slim down its midstream business. After selling off most of its natural gas liquid operations, the MLP will focus on oil. Midstream energy company ...

This AI system can analyze up to one million DNA letters at once, predicting how tiny changes in noncoding regions trigger everything from cancer to rare genetic disorders—and potentially ...

For decades, the dream of fixing harmful mutations in mitochondrial DNA felt out of reach. Scientists have long known these mutations cause serious diseases that pass down only through mothers.

Headquartered in Texas, Plains All American Pipeline, L.P. (NASDAQ:PAA) is a master limited partnership specializing in midstream energy infrastructure.

Shares of Plains All American Pipeline (PAA 0.30%) surged 10.8% in June, according to data provided by S&P Global Market Intelligence.

In a step toward treating mitochondrial diseases, researchers in the Netherlands have successfully edited harmful mutations in mitochondrial DNA using a genetic tool known as a base editor.

Koppens and colleagues reported on their findings in PLOS Biology in a paper titled “ Correction of pathogenic mitochondrial DNA in patient-derived disease models using mitochondrial base ...

In a step toward treating mitochondrial diseases, researchers in the Netherlands have successfully edited harmful mutations in mitochondrial DNA using a genetic tool known as a base editor. The ...

OrsoBio announces preclinical data on its mitochondrial protonophore portfolio at the American Diabetes Association’s 85th Scientific Sessions.